
A Crystal Ball for Cancer Survivors
This test can be thought of as a crystal ball for cancer survivors and research has found it can predict with near certainty whether a patient’s cancer will recur. So why aren't more patients getting the test?
This test can be thought of as a crystal ball for cancer survivors and research has found it can predict with near certainty whether a patient’s cancer will recur. So why aren't more patients getting the test?
Although the definition is evolving, truly personalized cancer care might be thought of as having four major pillars: interrogation of the cancer, predictive testing, inherited genes, and patient lifestyle, values and goals.
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.